Lonzabonemarrowmononuclearcells

BMNCsYouCanCountontoPerform

CryopreservedLonzaBoneMarrowMononuclearCellsareisolatedfromwholebonemarrowviadensitygrADIentseparation.Isolatingmononuclearcellseliminateserythrocytesandgraulocytes,producingamorestablecellproduct.

LonzaBMNCsareavailablefreshorfrozenfromalargeandvarieddonorpool.Theyareguaranteedtocontaineither≥5,25,100,or200millionviablecellsperampoule,dependinguponproductpurchased.

FreshcellsaresUSPendedinHBSSwith5mMEDTAand0.5%BSAandareavailable inavarietyof cellspervialpackagingsizes.FreshBMNCorders requireaminimumorder quantityoftwovialsperdonor.PleasecontactCustomerServiceforinformationonsizesandpricingforfreshcells.

ChoicesinCellTypeandTissueSource

Lonzaofferschoicesincelltypeandtissuesourcesoyoucanchoosetherightproductforyourresearchandbudgetneeds.Dependinguponyourultimatecellofchoice,youcanchoosefromunprocessedbonemarrow,bonemarrowMNCs,bonemarrowCD34+cells,bonemarrowCD133+cells,bonemarrowstromalcells(foruseasfeedercells),orbonemarrowmesenchymalstemcells.Inaddition,ifbonemarrowisnotyourpreferredtissuesource,wealsooffercordbloodderivedcells.

SupportedbyanOptimizedCultureSystem
HPGM™HematopoieticGrowthMediumisrecommendedforoptimalperformanceinserum-freeculturing(additionalcytokinesmaybenecessarydependingonapplication).Alternativemediacontainingserummayalsobeacceptable.PleasecontactScientificSupportforserumcontainingmediarecommendations.

LonzaguaranteestheperformanceofClonetics™/Poietics™cellsonlyifappropriateClonetics™/Poietics™mediaandreagentsareusedexclusivelyandtherecommendedstorageanduseprotocolsarefollowed.Anymodificationsmadetotherecommendedcellsystemsincludingtheuseofalternativemedia,reagentsorprotocols,willvoidcellandmediaperformanceguarantees.Ifyouneedassistanceinselectingtheappropriatemedia,reagents,orprotocol,pleasecontactLonzaScientificSupport.

Minimumorderquantityof2vialsperdonorisrequiredforfreshcells.HIV-1,hepatitisBandhepatitisCarenotdetectedforalldonorsand/orcelllots.ACertificateofAnalysisisprovidedforeachcelllotpurchased.

龙沙生物技术有限公司于2019年05月10日成立。法定代表人David Johann Wach，公司经营范围包括：生物技术开发服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;生物技术推广服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;生物技术咨询、交流服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;生物技术转让服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;医学研究和试验发展（人体干细胞、基因诊断与治疗技术除外）;药品研发（人体干细胞、基因诊断与治疗技术除外）;货物进出口(涉及外资准入特别管理规定和许可审批的商品除外);技术进出口;贸易代理;商品批发贸易（涉及外资准入特别管理规定和许可审批的商品除外）;生物药品制造;化学药品原料药制造;化学药品制剂制造等。